Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Acquisition

7 Mar 2006 07:04

Marchpole Holdings PLC07 March 2006 FOR IMMEDIATE RELEASE 7 March 2006 Marchpole Holdings plc ("Marchpole") MARCHPOLE COMPLETES ACQUISITION OF MODA AMERICA LLC Marchpole Holdings plc, which designs, produces and sells high quality clothingand accessories for six world class brands (Yves Saint Laurent, Boateng,Jean-Charles de Castelbajac ("JCC") and Jean-Charles de Castelbajac / Rossignol,Emanuel Ungaro and Ungaro), today announces the successful completion of itsacquisition of the whole of the issued share capital of Moda America LLC. Moda America is the US licensee for Emanuel Ungaro and the acquisition bringsfive key benefits : - Based on turnover of $20m in the year to 31st December 2005, primarily from major blue chip U.S. retail customers such as Federated, Macy's, Robinson May and Marshall Fields, the Directors anticipate that sales and margins will increase as Moda benefits from Marchpole's design, sourcing and production base. - Marchpole will be launching the diffusion Ungaro homme collection in the UK from Spring/Summer 2007. This collection will be priced at similar levels to the current YSL ranges which the Directors expect to have significant mass market appeal across Marchpole's existing customer base. - The presence of Marchpole in North America and the new distribution relationships accessed through this acquisition will facilitate the launch of the Jean Charles de Castelbajac brands in the US from Autumn/Winter 2006. - Marchpole's relationship with Emanuel Ungaro has been strengthened further, illustrated by the granting of womenswear distribution rights for the US. - The Emanuel Ungaro mainline collection, already established by Marchpole in Europe and Asia, will now be launched into the US, Canada and South America. Total consideration for the acquisition will be $5.5m in cash, to be satisfiedfrom the Company's existing resources, of which $1.0m was paid on completion andthe balance of $4.5m payable on 31st July 2006. Current Trading Outlook With the third quarter now complete and deliveries underway for the new Spring/Summer 2006 collections, the Directors remain confident of the Company meetingmarket expectations of profit before taxation for the current financial year of£5.0m. In addition, the Directors are intending to implement proposals to enable theCompany to buy-in its issued share capital subject to shareholder approval asthey believe that the current share price undervalues the Company and does notadequately reflect the strong future prospects of the business. Chairman Chris Phillips commented: "The acquisition contributes significantly to our strategic objective ofbecoming a truly worldwide manager of luxury brands". For further information contact: MarchpoleGreg Tufnell - Chief Executive 020 7908 7700 BuchananTim Thompson / Nicola Cronk 020 7466 5000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Sep 20191:00 pmRNSNotice of Results
6th Sep 20197:00 amRNSBlock listing Interim Review
4th Sep 20191:00 pmRNSMereo announces phase 2b data at ASBMR Meeting
16th Aug 20191:51 pmRNSDirector/PDMR Shareholding
15th Aug 20194:59 pmRNSPDMR Shareholding
12th Aug 20194:41 pmRNSSecond Price Monitoring Extn
12th Aug 20194:35 pmRNSPrice Monitoring Extension
9th Aug 20194:35 pmRNSPrice Monitoring Extension
31st Jul 201912:51 pmRNSDirector Declaration
25th Jul 20194:56 pmRNSPDMR Shareholding
24th Jul 201910:08 amRNSDirector/PDMR Shareholding
19th Jul 20191:21 pmRNSDirector/PDMR Shareholding
16th Jul 20191:00 pmRNSAppointment of Richard Francis
15th Jul 20191:00 pmRNSSuccessful Type B Meeting with U.S. FDA
8th Jul 20193:54 pmRNSHolding(s) in Company
3rd Jul 20194:41 pmRNSSecond Price Monitoring Extn
3rd Jul 20194:35 pmRNSPrice Monitoring Extension
27th Jun 20193:33 pmRNSHolding(s) in Company
26th Jun 20194:36 pmRNSHolding(s) in Company
21st Jun 20191:00 pmRNSConversion of loan note and issue of equity
20th Jun 20197:00 amRNSResult of AGM
13th Jun 20191:00 pmRNSUpdate on Etigilimab (TIGIT) Partnership
30th May 20197:00 amRNSPositive early 6 month data
23rd May 20194:11 pmRNSDirector/PDMR Shareholding
22nd May 20199:45 amRNSPDMR Shareholding
21st May 20193:08 pmRNSDirector/PDMR Shareholding
20th May 20197:00 amRNSNotice of AGM
8th May 20191:53 pmRNSDirector/PDMR Shareholding
7th May 20197:00 amRNSIssue of Warrants
7th May 20197:00 amRNSRe-release: Intention to Purchase Shares
3rd May 20195:00 pmRNSIntention to Purchase Shares by Trustee of EBT
3rd May 20192:02 pmRNSDirector/PDMR Shareholding
1st May 20193:47 pmRNSDirector/PDMR Shareholding
30th Apr 20193:15 pmRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSPublication of Annual Report and Accounts
29th Apr 20197:00 amRNSPrelims Results for year ended December 31 2018
26th Apr 20193:01 pmRNSDirector/PDMR Shareholding
25th Apr 20193:36 pmRNSHolding(s) in Company
25th Apr 20193:29 pmRNSHolding(s) in Company
24th Apr 20192:30 pmRNSAdmission to Trading
23rd Apr 20192:25 pmRNSCompletion of Merger
18th Apr 20197:00 amRNSMerger Update
15th Apr 20197:00 amRNSSuccessful end of Phase 2 Meeting with FDA
21st Mar 20197:00 amRNSPublication of Form F-4
15th Mar 201911:45 amRNSUpdate on Proposed Combination of Mereo & OncoMed
13th Mar 201911:00 amRNSMereo CEO appointed NED of Elanco Animal Health
6th Mar 20197:00 amRNSBlock Listing Interim Review
5th Mar 20191:32 pmRNSMereo to present at Cowen and Company Conference
22nd Feb 20191:50 pmRNSUpdate on Proposed Transaction with OncoMed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.